MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
Forest Laboratories (NYSE: FRX)
Finance & Acquisitions:Forest Labs
Clinical Data, Inc
Parents
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
*Architects: Diagnostics_In Vitro Diagnostics (IVD)
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies (Pharmaceuticals, Drugs, Biotechnology, Biosimilars)
*Industry: Massachusetts
*Portfolio Companies: Bioventure
Companies: Acquired_(M&A)
Finance & Acquisitions:Forest Labs
Children
2022: Randal Kirk, Overall Forbes rank: 1,818 (tied) Net worth in 2022: $1.6 billion, Net worth in 2021: $2.2 billion. Mr. Kirk, a former practicing attorney, is a former CEO of biotech company Intrexon, now named Precigen, and serves as CEO and chair of life-sciences investment firm Third Security.
Avalon Pharmaceuticals
Clinical Data, Inc provides comprehensive molecular and pharmacogenomics services as well as clinical diagnostics
Forest Laboratories to Acquire Clinical Data, Inc. for $1.2 billion (2011)
Newton, Massachusetts
Randal J. Kirk, CEO, Intrexeon, former CEO, New River,Board, Clinical Data
The Avalon Pharmaceuticals company was acquired by Clinical Data in 2009
The Clinical Data, Inc. transaction will allow Forest to extend its presence in the antidepressant category through the launch of Viibryd (vilazodone HCL tablets) which was approved by the FDA on January 21, 2011